1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Patient demographics
Institutional Cohort Total
Toronto Stanford
No. of patients 229 23 252
Age (mean) (yr) 8.18 6.32 8.01
Male (No.) (%) 124 (54.1%) 11 (47.8%) 135 (53.6%)
Histologic diagnosis (No.) 
 PA 112 16 128
 GG 24 5 29
 LGA 36 0 36
 PMA 8 2 10
 PXA 4 0 4
 DNET 10 0 10
 DA 17 0 17
 ODG 3 0 3
 GNT 5 0 5
 ACG 5 0 5
 NC 1 0 1
 DIG 1 0 1
 PLNTY 1 0 1
Mixed tumor components 2 0 2
Molecular subgroup (No.) (%) 
 KIAA1549-BRAF fusion 114 (49.7%) 18 (78.3%) 132 (52.2%)
 BRAF V600E mutation 36 (15.7%) 5 (21.7%) 41 (16.6%)
 Non-BRAF 79 (34.4%) 0 79 (31.2%)
 Supratentorial (No.) (%) 125 (54.5%) 5 (21.7%) 130 (51.8%)
 Infratentorial (No.) (%) 104 (45.4%) 18 (78.3%) 122 (48.2%)
Note:—ACG indicates angiocentric glioma; DA, diffuse astrocytoma; DIG, desmoplastic infantile ganglioglioma; DNET, dysembryoplastic neuroepithelial tumor; GNT, glioneural tumor; LGA, low-grade astrocytoma; NC, neurocytoma; PMA, pilomyxoid astrocytoma; PXA, pleomorphic xanthoastrocytoma; PLNTY, polymorphous low-grade neuroepithelial tumor of the young; ODG, oligodendroglioma.